Joe Jimenez: refocusing Novartis on pharmaceuticals, eyecare and generics

A near $50 billion (€36 billion) takeover battle for the maker of Botox and a multibillion-dollar asset swap between Novartis and Glaxo-SmithKline (...)

AstraZeneca shares surged by 8 per cent at one stage amid frenzied speculation that US rival Pfizer was preparing a mega-bid. Photograph: Chris Ratcliffe/Bloomberg

A flurry of deals and speculation of more to come has set the pharmaceuticals sector alight, sending shares in some of the UK’s biggest drugs g(...)

Eli Lilly said the deal is not expected to change its dividend policy or current share repurchase programme

Eli Lilly has confirmed it will buy Swiss drugmaker Novartis AG’s animal health business for $5.4 billion in cash to strengthen and diversify (...)

Netflix: results out today. Photograph: Gareth Cattermole/Getty Images for Netflix
For your diary

TODAY Results: Burger King; CBRE; First Bancorp; GNC Holdings; Hasbro; Netflix. Indicators: US Chicago Fed national activity index (Apr). (...)

Mark Lanier is no ordinary trial lawyer. His success has been such that he lives on a 25-acre estate near Houston and hosts lavish parties for (...)

Takeda Pharmaceutical’s shares fell as much as 8.8 per cent to an eight-month low in Tokyo trading today after the US federal jury verdict. Photograph: Kiyoshi Ota/Bloomberg

Takeda Pharmaceutical said it would contest $6 billion in punitive damages imposed by a US federal jury in a case alleging Japan’s largest drug(...)

Alkermes chief executive Richard Pops. Photograph: Dara Mac Dónaill / THE IRISH TIMES

Shares in Irish drug company Alkermes jumped over 10 per cent yesterday after it announced plans to seek US marketing approval for its experime(...)

The Lookout, by Brian O’Doherty, at Charles Fort for Kinsale Arts Festival. Photograph: John Allen

The arts aren’t unique: everyone has seen cuts to funding, but as artists and arts organisations are told to raise more money from an already s(...)

French drugmaker Sanofi is suing Eli Lilly and Co for alleged patent infringements concerning its top-selling Lantus diabetes treatment, delaying the (...)

GlaxoSmithKline said today European regulators had given the green light to its once-weekly diabetes drug albiglutide, which it is marketing as Eperza(...)